To the best of our knowledge, this is the first study to show the impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in patients with advanced NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.